Fed. Circ. Won't Eye Decision Upholding Teva Cancer Drug IP
The Federal Circuit won't rethink a panel's refusal to invalidate patents for Teva's cancer drug Bendeka, cementing a loss that Apotex and Mylan sustained at a lower court in a fight...To view the full article, register now.
Already a subscriber? Click here to view full article